Phase II study of erlotinib plus tivantinib (ARQ 197) in patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer just after progression on EGFR-TKI, gefitinib or erlotinib

BACKGROUND: Patients with epidermal growth factor receptor (EGFR) activation mutation-positive non-small-cell lung cancer (NSCLC) respond well to EGFR tyrosine kinase inhibitors (EGFR-TKIs), but eventually become resistant in most cases. The hepatocyte growth factor/c-Met (HGF/c-Met) pathway is repo...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:ESMO Open
Glavni autori: Azuma, Koichi, Hirashima, Tomonori, Yamamoto, Nobuyuki, Okamoto, Isamu, Takahashi, Toshiaki, Nishio, Makoto, Hirata, Taizo, Kubota, Kaoru, Kasahara, Kazuo, Hida, Toyoaki, Yoshioka, Hiroshige, Nakanishi, Kaoru, Akinaga, Shiro, Nishio, Kazuto, Mitsudomi, Tetsuya, Nakagawa, Kazuhiko
Format: Artigo
Jezik:Inglês
Izdano: BMJ Publishing Group 2016
Teme:
Original Research
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5070235/
https://ncbi.nlm.nih.gov/pubmed/27843623
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/esmoopen-2016-000063
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items